A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Subjects With Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Daratumumab (Primary) ; Pomalidomide (Primary) ; Talquetamab (Primary) ; Talquetamab (Primary) ; Teclistamab (Primary)
Indications Multiple myeloma
Focus Adverse reactions; First in man
Acronyms TRIMM-2
Sponsors Janssen Research & Development; Janssen-Cilag

03 Feb 2025 Planned End Date changed from 22 Aug 2025 to 7 Apr 2027.
01 Nov 2024 Planned primary completion date changed from 9 Sep 2024 to 22 Aug 2025.
27 Sep 2024 Results presented in a Janssen-Cilag Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com